Overactive Bladder and Cognitive Impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report
- 22 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 29 (1S) , S1-S19
Abstract
Importance: Overactive bladder (OAB) is prevalent in older adults in whom management is complicated by comorbidities and greater vulnerability to the cognitive effects of antimuscarinic medications. Objectives: The aim of this study is to provide a comprehensive evidence-based summary of the 2021 State-of-the-Science (SOS) conference and a multidisciplinary expert literature review on OAB and cognitive impairment. Study Design: The American Urogynecologic Society and the Pelvic Floor Disorders Research Foundation convened a 3-day collaborative conference. Experts from multidisciplinary fields examined cognitive function, higher neural control of the OAB patient, risk factors for cognitive impairment in older patients, cognitive effects of antimuscarinic medications for OAB treatment, OAB phenotyping, conservative and advanced OAB therapies, and the need for a multidisciplinary approach to person-centered treatment. Translational topics included the blood-brain barrier, purine metabolome, mechanotransduction, and gene therapy for OAB targets. Results: Research surrounding OAB treatment efficacy in cognitively impaired individuals is limited. Short- and long-term outcomes regarding antimuscarinic effects on cognition are mixed; however, greater anticholinergic burden and duration of use influence risk. Oxybutynin is most consistently associated with negative cognitive effects in short-term, prospective studies. Although data are limited, beta-adrenergic agonists do not appear to confer the same cognitive risk. Conclusions: The 2021 SOS summary report provides a comprehensive review of the fundamental, translational, and clinical research on OAB with emphasis on cognitive impairment risks to antimuscarinic medications. Duration of use and antimuscarinic type, specifically oxybutynin when examining OAB treatments, appears to have the most cognitive impact; however, conclusions are limited by the primarily cognitively intact population studied. Given current evidence, it appears prudent to minimize anticholinergic burden by emphasizing nonantimuscarinic therapeutic regimens in the older population and/or those with cognitive impairment.Keywords
This publication has 145 references indexed in Scilit:
- First Diagnosis and Management of Incontinence in Older People with and without Dementia in Primary Care: A Cohort Study Using The Health Improvement Network Primary Care DatabasePLOS Medicine, 2013
- Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS studyBMJ Open, 2013
- An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN‐D0501 in healthy subjectsBritish Journal of Clinical Pharmacology, 2011
- Diversity and Disparity in DementiaAlzheimer Disease & Associated Disorders, 2011
- Long term follow-up of a randomised controlled trial of services for urinary symptomsBMC Health Services Research, 2011
- Brain activity during bladder filling is related to white matter structural changes in older women with urinary incontinenceNeuroImage, 2010
- Dementia incidence continues to increase with age in the oldest old: The 90+ studyAnnals of Neurology, 2010
- Cerebral control of the bladder in normal and urge-incontinent womenNeuroImage, 2007
- Urinary Incontinence in Older Community-Dwelling WomenObstetrics & Gynecology, 2007
- Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid DiseasesJAMA, 2005